INVC NEWS health Desk
The Serum Institute of India (SII) has taken a commendable step amidst the increasing number of corona cases in India. The company has resumed manufacturing the Covishield vaccine, which will significantly contribute to the fight against the pandemic.
The Covid-19 pandemic has brought the world to its knees, and India has been no exception. The country has seen a massive surge in the number of cases over the past few months, which has put an enormous strain on the healthcare system. In such testing times, the decision of the SII to resume manufacturing of the Covishield vaccine is a glimmer of hope that the situation may soon be under control.
The CEO of SII, Adar Poonawalla, has announced that 6-7 million doses of the vaccine will be available in the next 90 days. This is good news for the country, which is currently battling a massive surge in cases. The Covishield vaccine has proven to be effective against the Covid-19 virus and has been administered to millions of people in India and around the world.
The Covishield vaccine is developed by Oxford University and AstraZeneca and is manufactured by the SII. It is one of the most effective vaccines available and has been authorized for emergency use by the World Health Organization (WHO). The vaccine has an efficacy rate of 70% against the Covid-19 virus and is being widely used in India’s vaccination drive.
The decision of the SII to resume manufacturing of the Covishield vaccine is a significant boost to India’s vaccination drive. The country has already vaccinated millions of people, but the recent surge in cases has highlighted the need to speed up the process. With the resumption of manufacturing, the SII will be able to provide more doses of the vaccine to the people of India and other countries that are in urgent need.
In addition to manufacturing the Covishield vaccine, the SII is also working on developing a nasal vaccine for Covid-19. The nasal vaccine is still in the trial phase, but it has shown promising results so far. If successful, the nasal vaccine will be a game-changer in the fight against the pandemic. It will be easier to administer, and it will be more effective against the Covid-19 virus.
Conclusion
In conclusion, the decision of the Serum Institute of India to resume manufacturing of the Covishield vaccine is a significant development in the fight against the Covid-19 pandemic. The vaccine has already proven to be effective in preventing the spread of the virus and has been authorized for emergency use by the World Health Organization. The resumption of manufacturing will provide much-needed relief to the healthcare system and will help speed up the vaccination drive.
The SII is also working on developing a nasal vaccine for Covid-19, which shows promising results. If successful, the nasal vaccine will be a game-changer in the fight against the pandemic. We hope that the SII will continue to innovate and contribute to the fight against Covid-19.
